Search Within

John Frank Gerecitano

Formats
  1. Meeting Abstract (100)
  2. Journal Article (51)
  3. Book Section (1)
  4. Book Whole (1)
Groups
  1. Department of Medicine (153)
  2. Hematologic Malignancies, Division of (153)
  3. Center for Hematologic Malignancies (82)
  4. Lymphoma (75)
  5. Survivorship Research (56)
  6. Executive Committee, Center for Hematologic Malignancies (45)

More Groups

People
  1. Andrew Zelenetz (62)
  2. Paul Hamlin (60)
  3. Craig Moskowitz (57)
  4. David Straus (56)
  5. Ariela Noy (50)
  6. Matthew Matasar (48)

More People

Years
  1. 2024 (1)
  2. 2022 (3)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (8)

More Years

Publications
  1. Blood (45)
  2. Journal of Clinical Oncology (34)
  3. Haematologica (11)
  4. Clinical Cancer Research (9)
  5. Hematological Oncology (8)
  6. Annals of Oncology (7)

More Publications

Publishers
  1. American Society of Hematology (46)
  2. American Society of Clinical Oncology (34)
  3. American Association for Cancer Research (11)
  4. Ferrata Storti Foundation (11)
  5. Wiley Blackwell (10)
  6. Oxford University Press (7)

More Publishers

Results (153)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated results of a phase II trial of bendamustine in relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Hamlin, P.; Gerecitano, J.; Horwitz, S.; Matasar, M.; Noy, A.; Palomba, M. L.; Portlock, C.; Straus, D.; Graustein, T.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save
  • Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-hodgkin lymphoma
    Journal Article

    Gerecitano, J.; Portlock, C.; Hamlin, P.; Moskowitz, C. H.; Noy, A.; Straus, D.; Schulman, P.; Dumitrescu, O.; Sarasohn, D.; Pappanicholaou, J.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Phase 1/2a study of navitoclax (abt-263) in relapsed or refractory lymphoid malignancies
    Meeting Abstract

    Wilson, H.; O'Connor, A.; Czuczman, S.; LaCasce, S.; Gerecitano, F.; Leonard, P.; Tulpule, A.; Xiong, H.; Chiu, Y. L.; Busman, T.; more...
    Haematologica (2010)

    Fulltext@MSK | Save
  • Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
    Journal Article

    Wilson, W. H.; O'Connor, O. A.; Czuczman, M. S.; LaCasce, A. S.; Gerecitano, J. F.; Leonard, J. P.; Tulpule, A.; Dunleavy, K.; Xiong, H.; Chiu, Y. L.; more...
    Lancet Oncology (2010)

    Fulltext@MSK | Save
  • Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes
    Journal Article

    O'Connor, O. A.; Portlock, C.; Moskowitz, C.; Hamlin, P.; Straus, D.; Gerecitano, J.; Gonen, M.; Dumitrescu, O.; Sarasohn, D.; Butos, J.; more...
    Clinical Cancer Research (2010)

    Fulltext@MSK | Save
  • A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL)
    Meeting Abstract

    Gerecitano, J. F.; O'Connor, O.; Van Deventer, H.; Hainsworth, J.; Leonard, J.; Afanasayev, B.; Chen, M.; Seroogy, J.; Escandon, R.; Wolff, A.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma
    Meeting Abstract

    Caces, D. D.; Halaas, J.; Hamlin, P.; Noy, A.; Kewalramani, T.; Portlock, C. S.; Zelenetz, A. D.; O'Connor, O. A.; Gerecitano, J. F.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): Final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim in patients with relapsed/refractory indolent and mantle cell lymphomas
    Meeting Abstract

    Gerecitano, J.; Portlock, C. S.; Hamlin, P. A.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Schulman, P.; Dumitrescu, O.; Sarasohn, D.; Pappanicholaou, J.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed Q14D without and with prophylactic G-CSF in non-Hodgkin (NHL) or Hodgkin lymphoma (HL)
    Meeting Abstract

    O'Connor, O. A.; Gerecitano, J.; Van Deventer, H.; Afanasyev, B.; Hainsworth, J.; Chen, M.; Saikali, K.; Seroogy, J.; Escandon, R.; Wolff, A.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • Phase 1/2a study of ABT-263 in relapsed or refractory lymphoid malignancies
    Meeting Abstract

    Wilson, W. H.; O'Connor, O. A.; Czuczman, M. S.; LaCasce, A.; Gerecitano, J.; Leonard, J. P.; Tulpule, A.; Xiong, H.; Chiu, Y. L.; Busman, T.; more...
    Blood (2009)

    Fulltext@MSK | Save